Research programme: encapsulated allosteric haemoglobin effector - ERYtech

Drug Profile

Research programme: encapsulated allosteric haemoglobin effector - ERYtech

Alternative Names: ENHOXY; GR-ARA1

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator ERYtech Pharma
  • Class Cell therapies; Inositol phosphates
  • Mechanism of Action Haemoglobin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Sickle cell anaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in France (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
  • 13 Jun 2012 The Committee for Orphan Medicinal Products of the EMA recommends orphan drug designation for encapsulated allosteric haemoglobin effector for sickle cell anaemia in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top